de los Pinos Elisabet
Known title: See RemarksCIK: 0001889633
Associated companies
Transaction History
| AURA | ▲ Buy | Grant | 166,000 | $0 | 3/2/2026 | View on chart |
| AURA | ▼ Sell | Open Market | 47,648 | $241K | 2/17/2026 | View on chart |
| AURA | ▼ Sell | Open Market | 16,928 | $82K | 1/20/2026 | View on chart |
| AURA | ▼ Sell | Open Market | 9,049 | $57K | 10/29/2025 | View on chart |
| AURA | ▲ Buy | Option Exercise | 10,948 | $56K | 6/2/2025 | View on chart |
| AURA | ▼ Sell | Tax Withholding | 9,948 | $61K | 6/2/2025 | View on chart |
| AURA | ▼ Sell | Open Market | 20,221 | $157K | 2/18/2025 | View on chart |
| AURA | ▲ Buy | Grant | 194,320 | $0 | 2/3/2025 | View on chart |
| AURA | ▼ Sell | Open Market | 15,955 | $122K | 1/21/2025 | View on chart |
| AURA | ▼ Sell | Open Market | 9,200 | $99K | 10/29/2024 | View on chart |
| AURA | ▲ Buy | Option Exercise | 24,992 | $68K | 10/18/2024 | View on chart |
| AURA | ▼ Sell | Open Market | 24,992 | $301K | 10/18/2024 | View on chart |
| AURA | ▲ Buy | Option Exercise | 5,474 | $32K | 9/27/2024 | View on chart |
| AURA | ▲ Buy | Grant | 162,935 | $0 | 2/1/2024 | View on chart |
| AURA | ▼ Sell | Open Market | 15,853 | $121K | 1/23/2024 | View on chart |
| AURA | ▲ Buy | Option Exercise | 3,800 | $10K | 11/6/2023 | View on chart |
| AURA | ▼ Sell | Open Market | 7,449 | $90K | 11/6/2023 | View on chart |
| AURA | ▼ Sell | Open Market | 9,586 | $65K | 10/30/2023 | View on chart |
| AURA | ▲ Buy | Grant | 121,875 | $0 | 1/19/2023 | View on chart |
| AURA | ▼ Sell | Open Market | 5,706 | $71K | 10/31/2022 | View on chart |
| AURA | ▼ Sell | Other | 4,552 | $0 | 11/2/2021 | View on chart |
| AURA | ▲ Buy | Grant | 74,357 | $0 | 10/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Aura Biosciences Announces Conference Participation and Inducement Grants
Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.
Aura Biosciences Announces Conference Participation and Inducement Grants. Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.